{"pmid":32500283,"pmcid":"PMC7272106","title":"ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic.","text":["ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic.","J Med Toxicol","Stolbach, Andrew I","Mazer-Amirshahi, Maryann","Marino, Ryan","Nelson, Lewis S","Sugarman, Jeremy","32500283"],"journal":"J Med Toxicol","authors":["Stolbach, Andrew I","Mazer-Amirshahi, Maryann","Marino, Ryan","Nelson, Lewis S","Sugarman, Jeremy"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500283","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s13181-020-00784-6","keywords":["covid-19","compassionate use","coronavirus","emergency use authorization","expanded access","off-label prescribing"],"weight":0,"_version_":1668890966324412417,"score":9.490897,"similar":[{"pmid":32418120,"title":"ACMT Position Statement: Medication Shortages During Coronavirus Disease Pandemic.","text":["ACMT Position Statement: Medication Shortages During Coronavirus Disease Pandemic.","J Med Toxicol","Mazer-Amirshahi, Maryann","Fox, Erin R","Farmer, Brenna Michelle","Stolbach, Andrew I","32418120"],"journal":"J Med Toxicol","authors":["Mazer-Amirshahi, Maryann","Fox, Erin R","Farmer, Brenna Michelle","Stolbach, Andrew I"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32418120","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s13181-020-00782-8","keywords":["covid-19","coronavirus","drug shortages","medication shortages","toxicology"],"topics":["Prevention"],"weight":1,"_version_":1667058206835212288,"score":72.01627},{"pmid":32237287,"pmcid":"PMC7169622","title":"COVID-19 Testing in South Korea: Current Status and the Need for Faster Diagnostics.","text":["COVID-19 Testing in South Korea: Current Status and the Need for Faster Diagnostics.","Ann Lab Med","Kim, Young Jin","Sung, Heungsup","Ki, Chang-Seok","Hur, Mina","32237287"],"journal":"Ann Lab Med","authors":["Kim, Young Jin","Sung, Heungsup","Ki, Chang-Seok","Hur, Mina"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32237287","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.3343/alm.2020.40.5.349","keywords":["covid-19","diagnostic testing","emergency use authorization","korea","outbreak","sars-cov-2"],"locations":["South Korea"],"countries":["Korea, Republic of"],"countries_codes":["KOR|Korea, Republic of"],"topics":["Diagnosis"],"weight":1,"_version_":1666138490366066688,"score":54.65207},{"pmid":32258351,"pmcid":"PMC7118644","title":"Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses.","text":["Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses.","Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on in vitro and in vivo studies (including some on a chemically related compound, GS-441524), which have demonstrated largely favorable findings. As the pandemic progresses, information from human compassionate use cases will continue to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community.","One Health","Amirian, E Susan","Levy, Julie K","32258351"],"abstract":["Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved therapies. In particular, the current coronavirus disease 2019 (COVID-19) pandemic has quickly intensified interest in developing treatment options to mitigate impact on human life. Remdesivir (GS-5734) is a broad-spectrum antiviral drug that is now being tested as a potential treatment for COVID-19 in international, multi-site clinical trials. Currently available evidence about the antiviral effects of remdesivir against coronaviruses is primarily based on in vitro and in vivo studies (including some on a chemically related compound, GS-441524), which have demonstrated largely favorable findings. As the pandemic progresses, information from human compassionate use cases will continue to accumulate before the clinical trials are concluded. It is imperative for public health practitioners and the One Health community to stay up to date on the most promising potential therapeutic options that are under investigation. Thus, the purpose of this review is to synthesize the knowledge to date about remdesivir as a therapeutic option for coronaviruses, with a special focus on information relevant to the One Health community."],"journal":"One Health","authors":["Amirian, E Susan","Levy, Julie K"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32258351","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.onehlt.2020.100128","keywords":["covid-19","compassionate use","coronavirus","gs-5734","remdesivir","sars-cov-2"],"e_drugs":["remdesivir"],"topics":["Treatment"],"weight":1,"_version_":1666138493138501632,"score":54.51006},{"pmid":32454981,"pmcid":"PMC7229878","title":"Current regulatory approaches for accessing potential COVID-19 therapies.","text":["Current regulatory approaches for accessing potential COVID-19 therapies.","This commentary aims to elaborate challenges in the regulatory approaches for accessing and investigating COVID-19 potential therapies either with off-label use, compassionate use, emergency use or for clinical trials. Since no therapies have been formally approved and completely effective and safe to date, the best clinical choice is acquired only after consistent and fair communication and collaboration between licensed clinicians, researchers, regulatory authorities, manufacturers and patients.","J Pharm Policy Pract","Halimi, Vesa","Daci, Armond","Stojanovska, Simona","Panovska-Stavridis, Irina","Stevanovic, Milena","Filipce, Venko","Grozdanova, Aleksandra","32454981"],"abstract":["This commentary aims to elaborate challenges in the regulatory approaches for accessing and investigating COVID-19 potential therapies either with off-label use, compassionate use, emergency use or for clinical trials. Since no therapies have been formally approved and completely effective and safe to date, the best clinical choice is acquired only after consistent and fair communication and collaboration between licensed clinicians, researchers, regulatory authorities, manufacturers and patients."],"journal":"J Pharm Policy Pract","authors":["Halimi, Vesa","Daci, Armond","Stojanovska, Simona","Panovska-Stavridis, Irina","Stevanovic, Milena","Filipce, Venko","Grozdanova, Aleksandra"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454981","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1186/s40545-020-00222-6","keywords":["covid-19","clinical practice","clinical studies","compassionate use","ema","emergency use","fda","off-label use","regulatory"],"topics":["Treatment"],"weight":1,"_version_":1667881798504284160,"score":50.904198}]}